Nivolumab Plus Brentuximab Vedotin for Low-Risk Relapsed Classic Hodgkin Lymphoma
Interview with David Henry MD
Related Articles
Musicians Face Lasting Side Effects After Breast Cancer Treatment
Dr Maurie Markman discusses a recent study describing musical toxicity following breast cancer treatment.
The Cancer Risk Hiding in Your Patient’s Glass: Rethinking Alcohol in Oncology
Alcohol’s link to cancer now goes beyond the big 7, reaching the prostate, pancreas, and stomach. Are you routinely asking patients about alcohol use? If…
GPs Urged to Improve Skin Cancer Care with Dermoscopy
With UK skin cancer cases rising, GPs have been encouraged to adopt dermoscopy, expand training, and consider lower-risk skin surgeries.
Ph-Positive Leukemia: No Longer a Death Sentence?
A quarter century of groundbreaking research has transformed the landscape for treating Philadelphia chromosome–positive leukemia.
Adjuvant Pertuzumab Shows OS Benefit in HER2 Breast Cancer
Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.
Can Remote Monitoring Reduce Hospitalizations in Patients With Cancer?
Researchers analyzed healthcare utilization outcomes following remote symptom monitoring enrollment in patients with cancer receiving systemic treatment.
Are US Cervical Cancer Screening Exit Criteria Failing?
A new modeling study estimates that the risk for cervical cancer is low in women who met criteria to stop screening, but real-world stats tell…
Anal Cancer Outcomes Improve on Lower-Dose Chemoradiotherapy
Short-term results from a recent trial suggest that reduced-dose chemoradiotherapy may achieve high local control with less toxicity in patients with early-stage anal cancer.
Can Intravenous Magnesium Prevent Cisplatin-Associated Acute Kidney Injury?
Prophylactic IV magnesium is associated with a reduced risk for cisplatin-associated acute kidney injury in patients with cancer.
Breast Cancer Mortality in Women Younger than 50 Years Plummets Over Decade, Racial Disparities Narrow
New research showed that breast cancer mortality in women aged 20-49 years dropped from 9.70 to 1.47 per 100,000 between 2010 and 2020, with improvements…